Ultragenyx (NASDAQ: RARE) granted 44,409 restricted stock units to 15 newly hired non-executive officers under its Employment Inducement Plan. The awards, approved by the compensation committee, were granted on June 16, 2026, as inducements in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest over four years, with 25% of shares vesting on each anniversary of the grant date, contingent on continued employment.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – RARE
+5.79%
+5.79%Session close to close
In the Jun 22 session, RARE gained 5.79%, reflecting a notable positive market reaction.
The stock moved +5.8% in the session following this news. A strong positive reaction aligns with rou...
Analysis
The stock moved +5.8% in the session following this news. A strong positive reaction aligns with routine but shareholder-friendly hiring incentives, as RSUs vest over four years. Elevated short interest near mid-teens could amplify upside but may reverse if insider selling persists.
Key Figures
Inducement RSUs granted:44,409 unitsNew non-executive officers:15 employeesVesting schedule:25% per year over 4 years+5 more
8 metrics
Inducement RSUs granted44,409 unitsRestricted stock units granted to new hires on June 16, 2026
New non-executive officers15 employeesRecipients of inducement RSU grants under employment plan
Vesting schedule25% per year over 4 yearsRSUs vest annually on each grant-date anniversary
Share price$27.43RARE pre-news price level from market context
Market capitalization$2,702,544,307Pre-news equity value for Ultragenyx
Short interest15.72%Short interest as of 2026-05-29 based on validated float
Volume vs average1.25xToday’s trading volume relative to 20-day average
Insider shares sold (90 days)24,002 sharesAggregate insider sales over last 90 days from Form 4 data
"reported the grant of 44,409 restricted stock units of the company’s common stock"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
nasdaq listing rule 5635(c)(4)regulatory
"as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
employment inducement planfinancial
"granted under the Ultragenyx Employment Inducement Plan, with a grant date of June 16, 2026"
An employment inducement plan is a package of pay, bonuses or stock-based awards offered to a new hire to persuade them to join a company, similar to a signing bonus or welcome offer. Investors care because these awards can increase payroll costs and dilute existing shares, while also signaling how much the company is spending to attract talent and align that new hire’s interests with shareholder value.
vestfinancial
"The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
NOVATO, Calif., June 19, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 44,409 restricted stock units of the company’s common stock to 15 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of June 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates.
About Ultragenyx Pharmaceutical Inc. Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx Investors & Media Joshua Higa (415) 475-6370
FAQ
What did Ultragenyx (NASDAQ: RARE) announce on June 19, 2026?
Ultragenyx announced it granted 44,409 restricted stock units to 15 newly hired non-executive officers. According to Ultragenyx, the grants were approved by the compensation committee and issued under the Ultragenyx Employment Inducement Plan as employment inducements in line with Nasdaq Listing Rule 5635(c)(4).
How many restricted stock units did Ultragenyx grant and to how many employees?
Ultragenyx granted 44,409 restricted stock units of its common stock to 15 newly hired non-executive officers. According to Ultragenyx, these equity awards are part of its Employment Inducement Plan and were provided as material inducements for the new employees to enter into employment with the company.
What is the vesting schedule for the new Ultragenyx (RARE) restricted stock units?
The granted Ultragenyx restricted stock units vest over four years, with 25% vesting on each anniversary of the grant date. According to Ultragenyx, vesting is contingent on each employee remaining continuously employed by the company on the applicable vesting dates throughout the four-year period.
When is the grant date for Ultragenyx’s June 2026 inducement RSU awards?
The grant date for Ultragenyx’s inducement restricted stock units is June 16, 2026. According to Ultragenyx, the compensation committee approved the awards under the Ultragenyx Employment Inducement Plan, with vesting beginning one year after this grant date and continuing annually over four years.
Why did Ultragenyx grant inducement restricted stock units under Nasdaq Listing Rule 5635(c)(4)?
Ultragenyx granted the restricted stock units as inducements material to new employees entering into employment. According to Ultragenyx, the awards were made under its Employment Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), which is referenced in connection with these employment-related equity grants.
Which employees received Ultragenyx’s June 2026 inducement RSU grants?
The June 2026 inducement restricted stock units were granted to 15 newly hired non-executive officers at Ultragenyx. According to Ultragenyx, these individuals received awards totaling 44,409 RSUs as part of their employment packages, subject to a four-year vesting schedule tied to continued employment.
